Company: RGNT
Filing Date: 2025-05-05
Form Type: F-1/A
Source: 0001213900-25-039589
Chunk: 21

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-05-05
Form: F-1/A
Chunk 21
---
25 million, assuming that the number of Ordinary Shares offered by us, as set forth on the cover page of this prospectus, remains the same and after deducting the estimated underwriting discounts and commissions and estimated offering expenses payable by us. Similarly, each increase (decrease) of 100,000 in the number of Ordinary Shares offered by us at the assumed initial public offering price would increase (decrease) each of cash, cash equivalents and short-term deposits, total assets and shareholders’ equity (deficiency) by $0.76 million.

<div align='center'>13

RISK FACTORS</div>

Investing in our Ordinary Shares involves a high degree of risk. You should carefully consider the risks and uncertainties described below, in addition to the other information set forth in this prospectus, including the consolidated financial statements and the related notes included elsewhere in this prospectus, before purchasing our securities. If any of the following risks actually occurs, our business, financial condition, cash flows and results of operations could be negatively impacted. In that case, the trading price of our Ordinary Shares would likely decline and you might lose all or part of your investment.

Risks Related to Our Financial Condition and Capital Requirements

We have a limited operating history and we have incurred significant operating losses since our inception, and anticipate that we will incur continued losses for the foreseeable future.

We are a development-stage
medical device company with a limited operating history. To date, we have focused almost exclusively on developing our lead product candidate,
GelrinC, and our Gelrin hydrogel technology platform. We have funded our operations to date primarily through the issuance of our equity
securities and convertible loans.

We have only a limited
operating history upon which you can evaluate our business and prospects. In addition, we have limited experience and have not yet demonstrated
an ability to successfully overcome many of the risks and uncertainties frequently encountered by companies in new and rapidly evolving
fields, particularly in the medical device industry. To date, we have not generated any revenue from the sale of our product candidate
(see “Management’s Discussion and Analysis of Financial Condition and Results of Operations” for additional information).
We have incurred losses in each year since our inception (except for 2024 as a result of a one-time research and development grant which
resulted in a one-time income), including net income of $5.2 million and a loss of $4.1 million for the years ended December 31, 2024
and 2023, respectively